Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Potential Biomarker for Oral Cancers Identified

By Biotechdaily staff writers
Posted on 03 Sep 2002
Researchers using a high-resolution gene mapping technique to investigate chromosomal band 11q13, present in extra copies in a large percentage of oral cancers, have identified a gene (tumor amplified and overexpressed sequence 1, or TAOS1) that may prove to be a useful biomarker in the diagnosis and prognosis of oral cancers. More...
Their study was published August 9, 2002, in the online version of the Proceedings of the National Academy of Sciences.

"Gene amplification is a common and critically important genetic defect in cancer cells, and chromosomal band 11q13 appears to be one of the most frequently amplified chromosomal regions,” said corresponding author Dr. Susanne M. Gollin, associate professor in the department of human genetics, University of Pittsburgh Cancer Institute (PA, USA; www.pitt.edu). "Our work represents the first time the structure of the 11q13 amplicon has been mapped so finely, enabling us to identify a new gene in this segment that is both amplified and overexpressed in oral cancer cells.”

Investigators examined 30 oral squamous cell carcinoma cell lines developed from tumors removed from patients who had not been treated previously. A technique called quantitative microsatellite analysis (QuMA) was used to map the 11q13 amplicon, which houses about 10 genes. Of the cell lines examined, 16 (63%) had amplification of band 11q13. Band 11q13 was found to contain the previously uncharacterized gene, TAOS1, which was both amplified and overexpressed in oral cancer cells. The data suggest that TAOS1 may be an amplification-dependent candidate oncogene with a role in the development and/or progression of human tumors, including oral squamous cell carcinomas.

"Due to its versatility, accuracy, and ability to produce high-resolution copy number measurements across the genome, QuMA should be helpful in examining this and other amplified genomic regions in a wide variety of tumors,” said senior author Dr. Tony E. Godfrey, assistant professor of surgery and human genetics at the University of Pittsburgh Cancer Institute.



Related Links:
University of Pittsburgh Medical Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.